Key Points
- Last month, FIGS reported that Q3 revenue rose 11% year-over-year, with management raising its full year outlook of expected 2023 revenue growth to approximately 8.5%.
- FIGS market share in the international healthcare apparel market is still less than 1%, an underappreciated long-term catalyst for the stock.
- If FIGS can execute on its growth initiatives and show signs of accelerating adoption, a multiyear run back to 2021 IPO levels in the $40’s holds 5x to 6x return potential.
- 5 stocks we like better than FIGS
Upgrade Now
This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.
Already have an account? Log in here.
Before you consider FIGS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FIGS wasn't on the list.
While FIGS currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
